Enjoy complimentary customisation on priority with our Enterprise License!
The Latin America Migraine Drugs Market size is forecast to increase by USD 80 million, at a CAGR of 5.4% between 2023 and 2028. The market is experiencing significant growth due to the increasing prevalence of migraine in the region. The market is further increased by the introduction of new classes of drugs with higher clinical efficacy, such as Calcitonin Gene-Related Peptide (CGRP) antagonists and monoclonal antibodies. However, concerns related to the side effects of migraine drugs, including medication overuse, headache, and cardiovascular risks, pose a challenge to market growth. Additionally, the affordability of these drugs remains a significant barrier to access for many patients in the region. Overall, the market trends indicate a shift towards more effective and safer treatment options, while addressing the affordability and accessibility challenges is crucial for market expansion.
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Therapy
7 Market Segmentation by End-user
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.